Major vault protein supports glioblastoma survival and migration by upregulating the EGFR/PI3K signalling axis

Oncotarget

Volumn 4, Issue 11, 2013, Pages 1904-1918

  Lötsch, Daniela ^a,b   Steiner, Elisabeth ^a   Holzmann, Klaus ^a   Spiegl Kreinecker, Sabine ^c   Pirker, Christine ^a   Hlavaty, Juraj ^d   Petznek, Helga ^d   Hegedus, Balazs ^b,e   Garay, Tamas ^e   Mohr, Thomas ^a   Sommergruber, Wolfgang ^f   Grusch, Michael ^a   Berger, Walter ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c KEPLER UNIVERSITY HOSPITAL   (Austria)

^d UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^e SEMMELWEIS UNIVERSITY   (Hungary)

^f BOEHRINGER INGELHEIM RCV GMBH AND CO KG   (Austria)

Author keywords

EGFR; Glioblastoma multiforme; Invasion; Major vault protein; PI3K

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; LUNG RESISTANCE PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN METASTASIS; CARCINOGENIC ACTIVITY; CELL INVASION; CELL MIGRATION; CELL SURVIVAL; CLONOGENESIS; CONTROLLED STUDY; FEMALE; GENE FUNCTION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MVP GENE; NONHUMAN; SIGNAL TRANSDUCTION; TRANSGENE; TUMOR GROWTH; TUMOR XENOGRAFT; UPREGULATION;

ADULT; ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MICE; MICE, SCID; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSFECTION; UP-REGULATION; VAULT RIBONUCLEOPROTEIN PARTICLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84890222150     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10(5):459-466.
2. Wen PY and Kesari S. Malignant gliomas in adults. N Engl J Med. 2008; 359(5):492-507.
3. Teodorczyk M and Martin-Villalba A. Sensing invasion: cell surface receptors driving spreading of glioblastoma. J Cell Physiol. 2010; 222(1):1-10.
4. Bredel M. Anticancer drug resistance in primary human brain tumors. Brain Res Brain Res Rev. 2001; 35(2):161-204.
5. Steiner E, Holzmann K, Elbling L, Micksche M and Berger W. Cellular functions of vaults and their involvement in multidrug resistance. Curr Drug Targets. 2006; 7(8):923-934.
6. Rome L, Kedersha N and Chugani D. Unlocking vaults: organelles in search of a function. Trends Cell Biol. 1991; 1(2-3):47-50.
7. Kickhoefer VA, Vasu SK and Rome LH. Vaults are the answer, what is the question? Trends Cell Biol. 1996; 6(5):174-178.
8. van Zon A, Mossink MH, Scheper RJ, Sonneveld P and Wiemer EA. The vault complex. Cell Mol Life Sci. 2003; 60(9):1828-1837.
9. Berger W, Steiner E, Grusch M, Elbling L and Micksche M. Vaults and the major vault protein: novel roles in signal pathway regulation and immunity. Cell Mol Life Sci. 2009; 66(1):43-61.
10. Kickhoefer VA, Rajavel KS, Scheffer GL, Dalton WS, Scheper RJ and Rome LH. Vaults are up-regulated in multidrug-resistant cancer cell lines. J Biol Chem. 1998; 273(15):8971-8974.
11. Mossink MH, van Zon A, Scheper RJ, Sonneveld P, Wiemer EA, Schoester M, Houtsmuller AB, Scheffer GL, Franzel-Luiten E, Kickhoefer VA, Mossink M, Poderycki MJ, Chan EK and Rome LH. Vaults: a ribonucleoprotein particle involved in drug resistance? Oncogene. 2003; 22(47):7458-7467.
12. Park K. The role of major vault protein (MVP) in drug resistance. J Control Release. 2012; 163(2):266.
13. Suprenant KA. Vault ribonucleoprotein particles: sarcophagi, gondolas, or safety deposit boxes? Biochemistry. 2002; 41(49):14447-14454.
14. Rome LH and Kickhoefer VA. Development of the Vault Particle as a Platform Technology. ACS Nano. 2012.
15. Steiner E, Holzmann K, Pirker C, Elbling L, Micksche M, Sutterluty H and Berger W. The major vault protein is responsive to and interferes with interferon-gamma-mediated STAT1 signals. J Cell Sci. 2006; 119(Pt 3):459-469.
16. Izquierdo MA, Scheffer GL, Flens MJ, Giaccone G, Broxterman HJ, Meijer CJ, van der Valk P and Scheper RJ. Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. Am J Pathol. 1996; 148(3):877-887.
17. Berger W, Spiegl-Kreinecker S, Buchroithner J, Elbling L, Pirker C, Fischer J and Micksche M. Overexpression of the human major vault protein in astrocytic brain tumor cells. Int J Cancer. 2001; 94(3):377-382.
18. Zhang R, Tremblay TL, McDermid A, Thibault P and Stanimirovic D. Identification of differentially expressed proteins in human glioblastoma cell lines and tumors. Glia. 2003; 42(2):194-208.
19. Johnson H, Del Rosario AM, Bryson BD, Schroeder MA, Sarkaria JN and White FM. Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts. Mol Cell Proteomics. 2012; 11(12):1724-1740.
20. Xue G and Hemmings BA. PKB/Akt-Dependent Regulation of Cell Motility. J Natl Cancer Inst. 2013.
21. Zoncu R, Efeyan A and Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011; 12(1):21-35.
22. Chung JH, Ginn-Pease ME and Eng C. Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) has nuclear localization signal-like sequences for nuclear import mediated by major vault protein. Cancer Res. 2005; 65(10):4108-4116.
23. Minaguchi T, Waite KA and Eng C. Nuclear localization of PTEN is regulated by Ca(2+) through a tyrosil phosphorylation-independent conformational modification in major vault protein. Cancer Res. 2006; 66(24):11677-11682.
24. Yu Z, Fotouhi-Ardakani N, Wu L, Maoui M, Wang S, Banville D and Shen SH. PTEN associates with the vault particles in HeLa cells. J Biol Chem. 2002; 277(43):40247-40252.
25. Lara PC, Pruschy M, Zimmermann M and Henriquez-Hernandez LA. MVP and vaults: a role in the radiation response. Radiat Oncol. 2011; 6:148.
26. Chugani DC, Kedersha NL and Rome LH. Vault immunofluorescence in the brain: new insights regarding the origin of microglia. J Neurosci. 1991; 11(1):256-268.
27. Aronica E, Gorter JA, Ramkema M, Redeker S, Ozbas-Gercerer F, van Vliet EA, Scheffer GL, Scheper RJ, van der Valk P, Baayen JC and Troost D. Expression and cellular distribution of multidrug resistance-related proteins in the hippocampus of patients with mesial temporal lobe epilepsy. Epilepsia. 2004; 45(5):441-451.
28. Liu B, Wang T, Wang L, Wang C, Zhang H and Gao GD. Up-regulation of major vault protein in the frontal cortex of patients with intractable frontal lobe epilepsy. J Neurol Sci. 2011; 308(1-2):88-93.
29. van Vliet EA, Aronica E, Redeker S and Gorter JA. Expression and cellular distribution of major vault protein: a putative marker for pharmacoresistance in a rat model for temporal lobe epilepsy. Epilepsia. 2004; 45(12):1506-1516.
30. Komori N, Takemori N, Kim HK, Singh A, Hwang SH, Foreman RD, Chung K, Chung JM and Matsumoto H. Proteomics study of neuropathic and nonneuropathic dorsal root ganglia: altered protein regulation following segmental spinal nerve ligation injury. Physiol Genomics. 2007; 29(2):215-230.
31. Li JY, Volknandt W, Dahlstrom A, Herrmann C, Blasi J, Das B and Zimmermann H. Axonal transport of ribonucleoprotein particles (vaults). Neuroscience. 1999; 91(3):1055-1065.
32. Pan HC, Lin JF, Ma LP, Shen YQ and Schachner M. Major vault protein promotes locomotor recovery and regeneration after spinal cord injury in adult zebrafish. Eur J Neurosci. 2012; 37(2):203-211.
33. Vasu SK and Rome LH. Dictyostelium vaults: disruption of the major proteins reveals growth and morphological defects and uncovers a new associated protein. J Biol Chem. 1995; 270(28):16588-16594.
34. Mossink MH, De Groot J, Van Zon A, Franzel-Luiten E, Schoester M, Scheffer GL, Sonneveld P, Scheper RJ and Wiemer EA. Unimpaired dendritic cell functions in MVP/LRP knockout mice. Immunology. 2003; 110(1):58-65.
35. Huse JT, Holland E and Deangelis LM. Glioblastoma: Molecular Analysis and Clinical Implications. Annu Rev Med. 2012; 64:59-70.
36. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA and Cavenee WK. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007; 21(21):2683-2710.
37. Kolli S, Zito CI, Mossink MH, Wiemer EA and Bennett AM. The major vault protein is a novel substrate for the tyrosine phosphatase SHP-2 and scaffold protein in epidermal growth factor signaling. J Biol Chem. 2004; 279(28):29374-29385.
38. Ryu SJ, An HJ, Oh YS, Choi HR, Ha MK and Park SC. On the role of major vault protein in the resistance of senescent human diploid fibroblasts to apoptosis. Cell Death Differ. 2008; 15(11):1673-1680.
39. Weber GL, Parat MO, Binder ZA, Gallia GL and Riggins GJ. Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells. Oncotarget. 2011; 2(11):833-849.
40. Ikeda R, Iwashita K, Sumizawa T, Beppu S, Tabata S, Tajitsu Y, Shimamoto Y, Yoshida K, Furukawa T, Che XF, Yamaguchi T, Ushiyama M, Miyawaki A, Takeda Y, Yamamoto M, Zhao HY, et al. Hyperosmotic stress up-regulates the expression of major vault protein in SW620 human colon cancer cells. Exp Cell Res. 2008; 314(16):3017-3026.
41. Koul D. PTEN signaling pathways in glioblastoma. Cancer Biol Ther. 2008; 7(9):1321-1325.
42. Li H and Yang BB. Stress response of glioblastoma cells mediated by miR-17-5p targeting PTEN and the passenger strand miR-17-3p targeting MDM2. Oncotarget. 2012; 3(12):1653-1668.
43. Taylor TE, Furnari FB and Cavenee WK. Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. Curr Cancer Drug Targets. 2012; 12(3):197-209.
44. Losert A, Lotsch D, Lackner A, Koppensteiner H, Peter-Vorosmarty B, Steiner E, Holzmann K, Grunt T, Schmid K, Marian B, Grasl-Kraupp B, Schulte-Hermann R, Krupitza G, Berger W and Grusch M. The major vault protein mediates resistance to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Lett. 2012; 319(2):164-172.
45. Mathieu V, Pirker C, Schmidt WM, Spiegl-Kreinecker S, Lotsch D, Heffeter P, Hegedus B, Grusch M, Kiss R and Berger W. Aggressiveness of human melanoma xenograft models is promoted by aneuploidy-driven gene expression deregulation. Oncotarget. 2012; 3(4):399-413.
46. Holzmann K, Ambrosch I, Elbling L, Micksche M and Berger W. A small upstream open reading frame causes inhibition of human major vault protein expression from a ubiquitous mRNA splice variant. FEBS Lett. 2001; 494(1-2):99-104.
47. Geback T, Schulz MM, Koumoutsakos P and Detmar M. TScratch: a novel and simple software tool for automated analysis of monolayer wound healing assays. Biotechniques. 2009; 46(4):265-274.
48. Fischer H, Taylor N, Allerstorfer S, Grusch M, Sonvilla G, Holzmann K, Setinek U, Elbling L, Cantonati H, Grasl-Kraupp B, Gauglhofer C, Marian B, Micksche M and Berger W. Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition. Mol Cancer Ther. 2008; 7(10):3408-3419.
49. Hegedus B, Zach J, Czirok A, Lovey J and Vicsek T. Irradiation and Taxol treatment result in non-monotonous, dose-dependent changes in the motility of glioblastoma cells. J Neurooncol. 2004; 67(1-2):147-157.
50. Berger W, Elbling L and Micksche M. Expression of the major vault protein LRP in human non-small-cell lung cancer cells: activation by short-term exposure to antineoplastic drugs. Int J Cancer. 2000; 88(2):293-300.
51. Heinzle C, Gsur A, Hunjadi M, Erdem Z, Gauglhofer C, Stattner S, Karner J, Klimpfinger M, Wrba F, Reti A, Hegedus B, Baierl A, Grasl-Kraupp B, Holzmann K, Grusch M, Berger W, et al. Differential Effects of Polymorphic Alleles of FGF Receptor 4 on Colon Cancer Growth and Metastasis. Cancer Res. 2012; 72(22):5767-5777.
52. Kowol CR, Heffeter P, Miklos W, Gille L, Trondl R, Cappellacci L, Berger W and Keppler BK. Mechanisms underlying reductant-induced reactive oxygen species formation by anticancer copper(II) compounds. J Biol Inorg Chem. 2012; 17(3):409-423.
53. Hlavaty J, Jandl G, Liszt M, Petznek H, Konig-Schuster M, Sedlak J, Egerbacher M, Weissenberger J, Salmons B, Gunzburg WH and Renner M. Comparative evaluation of preclinical in vivo models for the assessment of replicating retroviral vectors for the treatment of glioblastoma. J Neurooncol. 2011; 102(1):59-69.